CTLA4 and glioblastoma: The aim of this clinical trial is to exploit the potential synergy of combined intratumor anti-CTLA-4 mAb (ipilimumab) with systemic PD-1 blockade with nivolumab, while minimizing risks for immune-related toxicity of ipilimumab following resection of recurrent glioblastoma.